GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: dithio-(Rp,Rp)-[cyclic[A(2',5')pA(3',5')p]] | MIW815 | ML RR-S2 CDA [1] | S100
Compound class:
Synthetic organic
Comment: ADU-S100 (a.k.a. ML RR-S2 CDA) is a synthetic cyclic dinucleotide STING agonist that is being developed as an immuno-oncology lead by Aduro BioTech and Novartis [1].
|
|
No information available. |
Summary of Clinical Use ![]() |
ADU-S100 has been advanced to Phase 1 clinical evaluation as a adjunct to immune checkpoint inhibitors in solid and hematological tumours. Click here to link to ClinicalTrials.gov's full list of ADU-S100 trials. |